Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Raymond James Initiates Coverage On Dianthus Therapeutics with Outperform Rating, Announces Price Target of $24

Author: Benzinga Newsdesk | September 28, 2023 09:14am
Raymond James analyst Steven Seedhouse initiates coverage on Dianthus Therapeutics (NASDAQ:DNTH) with a Outperform rating and announces Price Target of $24.

Posted In: DNTH

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist